Announcement of Exclusive Sales Agreement for Tuberculosis Chemotherapy Drug ‘Satchuro® Tablets’ in Japan

Overview of the Agreement

Kyorin Pharmaceutical concluded an exclusive sales agreement in Japan for 'Satchuro® Tablets 100mg', a tuberculosis chemotherapy drug with Johnson & Johnson (J&J) on March 25, 2026. Satchuro® Tablets are used as combination therapy for multidrug-resistant pulmonary tuberculosis and are currently marketed by J&J. Kyorin Pharmaceutical plans to begin sole promotional activities from June 2026 and will procure products from J&J for exclusive sales following additional approval for pulmonary MAC disease indications.

Future Outlook and Impact

This agreement aligns with Kyorin Pharmaceutical’s medium-term management plan 'Vision 110 – Stage1 –' focusing on acquiring introduced products and is part of a franchise customer strategy targeting specialized fields such as pulmonology, otolaryngology, and urology. Aiming to contribute to the treatment of infectious disease patients, the impact on consolidated earnings guidance for the fiscal year ending March 2026 is expected to be minimal. There are no capital, personnel, or transactional relationships with J&J.